A state-of-the-art pilot line environment established by VTT Technical Research Centre of Finland aims to bridge the critical gap between medical technology research and market-ready products, potentially reducing development timelines for non-invasive diagnostic and monitoring devices.
BioMed X Institute has announced a groundbreaking partnership with the Government of Barbados to launch BioMed X Barbados, a new research initiative tackling healthcare disparities in cardiometabolic disease treatment. The collaboration, supported by the European Commission’s PharmaNext programme, aims to address the underrepresentation of people of African descent in clinical research through advanced molecular characterisation […]
The revolutionary UV-150 photochemical reactor, employed alongside Vapourtec’s R-Series flow chemistry system, has enabled significant advancements in peptide modification techniques with potential to reshape pharmaceutical manufacturing.
Global healthcare company Sanofi has successfully priced a €1.5 billion bond issue, structured across two tranches with different maturity profiles and interest rate mechanisms. The financing move, announced on 5 March 2025, represents a significant capital raising exercise that strengthens the company’s financial position.
FORESIGHT consortium receives €9 million grant to accelerate drug development through advanced imaging technologies, addressing challenges in treating rising disease burdens across multiple therapeutic areas.
The Cambridge-based biotech company Shift Bioscience has announced the establishment of new facilities in Toronto, Canada, marking a strategic expansion of their AI capabilities in the development of virtual cell technology. The move follows their recent $16M seed funding round and positions the company to tap into North America’s rich pool of artificial intelligence talent.
Artificial Inc has successfully demonstrated the integration of NVIDIA’s BioNeMo generative AI platform with its laboratory orchestration system, showcasing capabilities for self-driving virtual screening in drug discovery applications. The proof-of-concept represents a significant technical advancement in applying AI technologies to pharmaceutical research workflows.
Sapio Sciences has announced significant leadership changes designed to strengthen its position in the AI-driven lab informatics sector. The Baltimore-based company, known for its “science-aware” platform, has appointed Mike Hampton as Chief Commercial Officer while simultaneously establishing a dedicated Scientific Office to enhance its research and development capabilities.
bioMérieux has announced the acquisition of SpinChip Diagnostics ASA, a privately held Norwegian company specialising in rapid immunoassay diagnostics. The €138 million deal will see bioMérieux acquire 100% ownership of the company, with a cash outlay of approximately €111 million, accounting for the 20% minority stake bioMérieux has held since March 2024.
Nuclera, the Cambridge-based biotechnology company focused on accelerating protein expression and optimisation, has appointed William J. Kullback to its Board of Directors. The appointment comes as the company implements its global commercial strategy following a successful $75 million series C funding round.
February | March 2025
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.